Abstract:Objectives-To assess the efficacy and safety of ultrasound-guided percutaneous ablation (US-PA) for adrenal metastases (AMs) using a meta-analysis.Methods-A systematic search of PubMed, Cochrane, Web of Science, and Embase electronic databases was performed to identify studies on US-PA for AM. Seven studies published between January 2000 and August 2022 were analyzed, which resulted in a sample size of 140 patients. Both random effects and common effects meta-analysis models were used to analyze the following … Show more
“…Comparative studies reveal success rates for cryoablation, radiofrequency, and microwave ablation for AMs ranging from 70.5% to 82% [1][2][3][14][15][16][17][18][19].…”
Section: Discussionmentioning
confidence: 99%
“…The increasing occurrence of metastatic tumors in the adrenal glands, originating from various types of cancers such as lung, breast, colorectal, hepatocellular carcinoma (HCC), and melanoma, presents substantial challenges in the field of oncology [1][2][3][4].…”
Section: Introductionmentioning
confidence: 99%
“…While the efficacy of direct adrenal interventions is yet to be established through randomized studies, the role of surgical resection, particularly for isolated adrenal metastases, has gained recognition in observational studies. [7][8][9][10][11] However, surgical procedures like adrenalectomy are often hampered by individual health concerns and the intricacies of the operations, resulting in prolonged hospital admissions [1][2][3][4].…”
Section: Introductionmentioning
confidence: 99%
“…In contrast, Computed Tomography (CT)-guided methods such as radiofrequency and microwave ablation have demonstrated encouraging one-year survival rates without local recurrence, ranging from 70.5% to 82% in the treatment of adrenal metastases [1][2][3].…”
Background:
To assess effectiveness, safety of computed tomography (CT)-guided cryoablation for treating adrenal metastases (AMs).
Materials and Methods:
This study involved 12 patients treated with 13 CT-guided cryoablation procedures for AMs between 2016 and 2020.
Patients’ ineligible for surgery, with tumors ≤5 cm, and no significant health risks were included. The procedures, conducted by expert radiologists, included initial non-contrast CT scans to determine lesion morphology, followed by cryoablation with monitoring for complications.
Post-treatment, patients underwent regular physical and laboratory checks, including hormonal analysis, and CT scans at specified intervals to assess the treatment's effectiveness and detect disease recurrence or progression.
Results:
In this study, 12 patients with AMs successfully underwent cryoablation, achieving a primary technical success rate of 91.7% and a secondary rate of 100% after a repeat procedure for one patient.
All cryoablation sessions were completed without major complications, with ice ball formations extending 1 cm beyond tumor margins to ensure safety.
Over an 8–24-month follow-up (average 16.3 months), six patients required further systemic therapy, with three developing extra-adrenal tumors. Local progression was noted in two patients (16.7%), one of whom underwent a repeat cryoablation.
Systemic progression was observed in five patients, involving renal and NSCLC cancer recurrences and bone metastasis.
The study reported five deaths due to tumor progression and heart failure, with an average overall survival duration of 32.4 ± 7.6 months.
“…Comparative studies reveal success rates for cryoablation, radiofrequency, and microwave ablation for AMs ranging from 70.5% to 82% [1][2][3][14][15][16][17][18][19].…”
Section: Discussionmentioning
confidence: 99%
“…The increasing occurrence of metastatic tumors in the adrenal glands, originating from various types of cancers such as lung, breast, colorectal, hepatocellular carcinoma (HCC), and melanoma, presents substantial challenges in the field of oncology [1][2][3][4].…”
Section: Introductionmentioning
confidence: 99%
“…While the efficacy of direct adrenal interventions is yet to be established through randomized studies, the role of surgical resection, particularly for isolated adrenal metastases, has gained recognition in observational studies. [7][8][9][10][11] However, surgical procedures like adrenalectomy are often hampered by individual health concerns and the intricacies of the operations, resulting in prolonged hospital admissions [1][2][3][4].…”
Section: Introductionmentioning
confidence: 99%
“…In contrast, Computed Tomography (CT)-guided methods such as radiofrequency and microwave ablation have demonstrated encouraging one-year survival rates without local recurrence, ranging from 70.5% to 82% in the treatment of adrenal metastases [1][2][3].…”
Background:
To assess effectiveness, safety of computed tomography (CT)-guided cryoablation for treating adrenal metastases (AMs).
Materials and Methods:
This study involved 12 patients treated with 13 CT-guided cryoablation procedures for AMs between 2016 and 2020.
Patients’ ineligible for surgery, with tumors ≤5 cm, and no significant health risks were included. The procedures, conducted by expert radiologists, included initial non-contrast CT scans to determine lesion morphology, followed by cryoablation with monitoring for complications.
Post-treatment, patients underwent regular physical and laboratory checks, including hormonal analysis, and CT scans at specified intervals to assess the treatment's effectiveness and detect disease recurrence or progression.
Results:
In this study, 12 patients with AMs successfully underwent cryoablation, achieving a primary technical success rate of 91.7% and a secondary rate of 100% after a repeat procedure for one patient.
All cryoablation sessions were completed without major complications, with ice ball formations extending 1 cm beyond tumor margins to ensure safety.
Over an 8–24-month follow-up (average 16.3 months), six patients required further systemic therapy, with three developing extra-adrenal tumors. Local progression was noted in two patients (16.7%), one of whom underwent a repeat cryoablation.
Systemic progression was observed in five patients, involving renal and NSCLC cancer recurrences and bone metastasis.
The study reported five deaths due to tumor progression and heart failure, with an average overall survival duration of 32.4 ± 7.6 months.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.